Metformina + Sitagliptina Generis

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformina + Sitagliptina Generis, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control.

GNH USA supplies Metformina + Sitagliptina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Generis is indicated for the management of type 2 diabetes mellitus, a chronic disorder of glucose metabolism. - Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise. - Inadequate control on metformin alone: provides additional glucose lowering as part of combination therapy. - Adjunct to other antidiabetic agents: enhances overall efficacy of multi‑drug regimens.

Metformina + Sitagliptina Generis may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Mild hypoglycemia (when used with other glucose‑lowering agents) - Metallic taste

Serious or Rare Side Effects: - Lactic acidosis - Severe skin reactions such as Stevens‑Johnson syndrome - Acute pancreatitis - Hepatic failure - Anaphylactic reactions - Severe hypoglycemia

Before prescribing Metformina + Sitagliptina Generis, clinicians should consider several safety measures. - Renal function: assess creatinine clearance before initiation and periodically. - Hepatic function: evaluate liver disease risk due to lactic acidosis potential. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Elderly patients: start at lower dose and monitor tolerance. - Concomitant medications: review for drugs that may affect renal clearance or increase hypoglycemia risk. - Store at room temperature: keep in original container, protect from moisture and heat.

Metformina + Sitagliptina Generis can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal impairment increasing metformin accumulation. - Cimetidine: can raise metformin plasma concentrations. - Excessive alcohol intake: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, necessitating monitoring. - Diuretics: can alter renal clearance of metformin. - Other antidiabetic agents: increase risk of hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms.